A new STEP story highlights how EU support is helping advance an innovative gene therapy for Parkinson’s disease at Mazowiecki Szpital Bródnowski in Warsaw.
Parkinson’s disease is the second most common neurodegenerative disorder, affecting around 1.2 million people across Europe. Backed by €46.1 million from the European Regional Development Fund, the project is developing a treatment that uses a viral vector to deliver a therapeutical gene directly into specific areas of the brain using advanced neurosurgery and real-time imaging. The therapy aims to slow disease progression, improve motor functions and enhance patients’ quality of life.
The project is a concrete example of how STEP is reinforcing Europe's strategic strengths in biotechnology, supporting bold, innovative projects whilst building the continent's long-term competitiveness in critical technologies.
Details
- Publication date
- 7 May 2026
- Author
- Directorate-General for Budget
Related links
Discover STEP
Read more about STEP and its results
Learn about the Strategic Technologies for Europe Platform (STEP): its mission to boost EU investment in critical technologies, its scope and its synergies with 11 EU funding programmes. Driving innovation and competitiveness across Europe.
Discover innovative projects in digital, clean, bio and defence technology sectors and explore how they shape the future of innovation in Europe.
Funding allocations, STEP Seal projects, and sectoral investment trends in digital, clean-tech, and biotech. See how EU investments drive innovation and strategic autonomy.
